Table 2. In participants who made as per protocol visits, IgG and IgA titres in 9-month and 12-month groups.
| 9-month | 12-month | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Visit 1 Primary dose | Visit2 28 days post-primary | Visit 3 Booster dose |
Visit 4 28 days Post-booster | Visit 1 Primary dose | Visit2 28 days post-primary | Visit 3 Booster dose |
Visit 4 28 days Post-booster | ||
| IgG | |||||||||
| Level above the lower limit of quantification of the assay | 4/50 (8 %) | 27/27 (100 %) | 32/32 (100 %) | 20/20 (100 %) | 5/50 (10 %) | 32/32 (100 %) | 16/16 (100 %) | 10/10 (100 %) | |
| Geometric mean concentration (95 % CI), EU per mL |
4.27 (3.60–5.06) |
3223.51 (2302.10–4513.71) |
302.848 (235.845–388.89) |
2249.26 (1701.02–2974.19) |
4.30 (3.67to5.04) |
2533.10 (2069.10–3101.15) |
1049.01 (762.07–1443.99) |
1173.43 (740.17–1860.31) |
|
| Median (IQR) | 3.7 (3.7–3.7) | 2854.66 (1871.47–6023.04) |
332.1115 (174.97–472.62) | 2151.273 (1396.04 to 3029.45) | 3.7 (3.7–3.7) | 2278.40 (1725.07–4147.27) |
918.21 (727.17–1501.6) | 1745.12 (1099.2–2492.64) |
|
| IgA | |||||||||
| Level above the lower limit of quantification of the assay | 3/50 (6 %) | 27/27 (100 %) | 28/32 (87.5 %) | 20/20 (100 %) | 6/50 (12 %) | 32/32 (100 %) | 16/16 (100 %) | 9/10 (90 %) | |
| Geometric mean concentration (95 % CI), EU per mL |
1.66 (1.54–1.77) |
51.80 (35.42–75.75) | 9.88 (7.01–13.92) | 26.87 (19.84– 36.39) | 1.83 (1.58–2.11) |
48.96 (37.02–64.73) | 28.31 (18.11–44.25) | 25.29 (11.32–56.52) | |
| Median (IQR) | 1.56 (1.56 to1.56) |
56.74 (28.09–77.06) | 10.06 (6.20–19.68) | 24.96 (18.44–45.56) | 1.56 (1.56 to1.56) |
46.51 (29.75–69.52) | 25.26 (18.20–43.92) | 31.71 (24.79–42.97) | |